<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MICARDIS - telmisartan tablet </strong><br>Physicians Total Care, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use MICARDIS safely and effectively. See full prescribing information for MICARDIS.<br><br>
		MICARDIS<span class="Sup">®</span> (telmisartan) Tablets<br>
		Initial U.S. Approval: 1998</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold"><span class="Emphasis">WARNING:  FETAL TOXICITY</span></span></h1>
<h1 class="Warning">
<span class="Italics"><span class="Emphasis">See full prescribing information for complete boxed warning</span></span>.</h1>
<ul class="Disc">
<li><span class="Bold"><span class="Emphasis">When pregnancy is detected, discontinue MICARDIS as soon as possible <a href="#Section_5.1">(5.1)</a></span></span></li>
<li>
<span class="Bold"><span class="Emphasis">Drugs that act directly on the renin-angiotensin system can cause injury and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus <a href="#Section_5.1">(5.1)</a></span></span>.</li>
</ul>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold"><span class="Emphasis">WARNING:  FETAL TOXICITY</span></span></h1>
<h1 class="Warning">
<span class="Italics"><span class="Emphasis">See full prescribing information for complete boxed warning</span></span>.</h1>
<ul class="Disc">
<li><span class="Bold"><span class="Emphasis">When pregnancy is detected, discontinue MICARDIS as soon as possible <a href="#Section_5.1">(5.1)</a></span></span></li>
<li>
<span class="Bold"><span class="Emphasis">Drugs that act directly on the renin-angiotensin system can cause injury and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus <a href="#Section_5.1">(5.1)</a></span></span>.</li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">MICARDIS is an angiotensin II receptor blocker (ARB) indicated for: </p>
<ul class="Disc">
<li>Treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> <a href="#Section_1.1">(1.1)</a>
</li>
<li>Cardiovascular (CV) risk reduction in patients unable to take ACE inhibitors <a href="#Section_1.2">(1.2)</a>
</li>
</ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<ul class="Disc">
<li>May be administered with or without food <a href="#Section_2.1">(2.1)</a>
</li>
<li>When used for cardiovascular risk reduction, monitoring of blood pressure is recommended, and if appropriate, adjustment of medications that lower blood pressure may be necessary <a href="#Section_2.2">(2.2)</a>
</li>
</ul>
<a name="ied3e7811-0b92-4feb-8173-8c11db00674f"></a><table border="1" cellpadding="1" cellspacing="0" width="60%"><tbody class="Headless">
<tr class="First">
<th align="left">Indication</th>
<th align="left">Starting Dose</th>
<th align="left">Dose Range</th>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> <a href="#Section_2.1">(2.1)</a>
</td>
<td align="left">40 mg once<br> daily</td>
<td align="left">40 to 80 mg once<br> daily</td>
</tr>
<tr class="Last">
<td align="left">Cardiovascular<br> Risk Reduction <a href="#Section_2.2">(2.2)</a>
</td>
<td align="left">80 mg once<br> daily</td>
<td align="left">80 mg once<br> daily</td>
</tr>
</tbody></table>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>Tablets: 20 mg, 40 mg, 80 mg <a href="#Section_3">(3)</a>
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc"><li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> or <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>) to telmisartan or any other component of this product <a href="#Section_4">(4)</a>
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Avoid fetal or neonatal exposure <a href="#Section_5.1">(5.1)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>: Correct any volume or <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">salt depletion</span> before initiating therapy.  Observe for signs and symptoms of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> <a href="#Section_5.2">(5.2)</a>
</li>
<li>Monitor carefully in patients with impaired hepatic <a href="#Section_5.4">(5.4)</a> or renal function <a href="#Section_5.5">(5.5)</a>
</li>
<li>Avoid concomitant use of an ACE inhibitor and angiotensin receptor blocker <a href="#Section_5.6">(5.6)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>:  The most common adverse events (≥1%) reported in <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> trials are <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> <a href="#Section_6.1">(6.1)</a>
</li>
<li>Cardiovascular risk reduction:  The serious adverse events (≥1%) reported in cardiovascular risk reduction trials were <span class="product-label-link" type="condition" conceptid="442774" conceptname="Intermittent claudication">intermittent claudication</span> and <span class="product-label-link" type="condition" conceptid="4262920" conceptname="Skin ulcer">skin ulcer</span> <a href="#Section_6.1">(6.1)</a><br>
</li>
</ul>
<p class="Highlighta"><span class="Bold"><span class="Emphasis">To report SUSPECTED ADVERSE REACTIONS, contact Boehringer Ingelheim Pharmaceuticals, Inc. at (800) 542-6257 or (800) 459-9906
TTY, or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch.</span></span></span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc"><li>NSAID use may lead to increased risk of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and loss of antihypertensive effect <a href="#Section_7">(7)</a>
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>Nursing Mothers: Choose to discontinue nursing or drug <a href="#Section_8.3">(8.3)</a>
</li>
<li>Geriatric Patients: No overall difference in efficacy or safety vs younger patients, but greater sensitivity of some older individuals cannot be ruled out <a href="#Section_8.5">(8.5)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 2/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING:  FETAL TOXICITY</a></h1>
<h1><a href="#section-1" class="toc">1  INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1  Hypertension</a></h2>
<h2><a href="#section-1.2" class="toc">1.2  Cardiovascular Risk Reduction</a></h2>
<h1><a href="#section-2" class="toc">2  DOSAGE AND ADMINISTRATION </a></h1>
<h2><a href="#section-2.1" class="toc">2.1  Hypertension</a></h2>
<h2><a href="#section-2.2" class="toc">2.2  Cardiovascular Risk Reduction</a></h2>
<h1><a href="#section-3" class="toc">3  DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4  CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5  WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1  Fetal Toxicity</a></h2>
<h2><a href="#section-5.2" class="toc">5.2  Hypotension</a></h2>
<h2><a href="#section-5.3" class="toc">5.3  Hyperkalemia</a></h2>
<h2><a href="#section-5.4" class="toc">5.4  Impaired Hepatic Function</a></h2>
<h2><a href="#section-5.5" class="toc">5.5  Impaired Renal Function</a></h2>
<h2><a href="#section-5.6" class="toc">5.6  Dual Blockade of the Renin-Angiotensin-Aldosterone System</a></h2>
<h1><a href="#section-6" class="toc">6  ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1  Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2  Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7  DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8  USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1  Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3  Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4  Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5  Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6  Hepatic Insufficiency</a></h2>
<h1><a href="#section-9" class="toc">10  OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11  DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12  CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1  Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2  Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3  Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13  NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.3  Developmental Toxicity</a></h2>
<h1><a href="#section-13" class="toc">14  CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1  Hypertension</a></h2>
<h2><a href="#section-13.2" class="toc">14.2  Cardiovascular Risk Reduction</a></h2>
<h1><a href="#section-14" class="toc">16  HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17  PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1  Pregnancy</a></h2>
<h2><a href="#section-15.2" class="toc"></a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="Section_00"></a><a name="section-1"></a><p></p>
<h1>WARNING:  FETAL TOXICITY</h1>
<ul class="Disc">
<li>
<span class="Bold"><span class="Emphasis">When pregnancy is detected, discontinue MICARDIS as soon as possible <span class="Italics">[see Warnings and Precautions <a href="#Section_5.1">(5.1)</a>]</span></span></span>.</li>
<li>
<span class="Bold"><span class="Emphasis">Drugs that act directly on the renin-angiotensin system can cause injury and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus <span class="Italics">[see Warnings and Precautions <a href="#Section_5.1">(5.1)</a>]</span></span></span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_1"></a><a name="section-1"></a><p></p>
<h1>1  INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1  Hypertension</h2>
<p class="First">MICARDIS is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.  It may be used alone or in combination with other antihypertensive agents <span class="Italics"><span class="Emphasis">[see
Clinical Studies <a href="#Section_14.1">(14.1)</a>]</span></span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2  Cardiovascular Risk Reduction</h2>
<p class="First">MICARDIS is indicated for reduction of the risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take ACE inhibitors.</p>
<p>High risk for cardiovascular events can be evidenced by a history of <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, peripheral arterial disease, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, transient ischemic attack, or high-risk <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (insulin-dependent or non-insulin dependent) with evidence of end-organ damage <span class="Italics"><span class="Emphasis">[see Clinical Studies <a href="#Section_14.2">(14.2)</a>]</span></span>.  MICARDIS can be used in addition to other needed treatment (such as antihypertensive, antiplatelet or lipid-lowering therapy) <span class="Italics"><span class="Emphasis">[see Clinical Studies <a href="#Section_14.2">(14.2)</a>]</span></span>.</p>
<p>Studies of telmisartan in this setting do not exclude that it may not preserve a meaningful fraction of the effect of the ACE inhibitor to which it was compared. Consider using the ACE inhibitor first, and, if it is stopped for <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> only, consider re-trying the ACE inhibitor after the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> resolves.</p>
<p>Use of telmisartan with an ACE inhibitor is not recommended <span class="Italics"><span class="Emphasis">[see Warnings and Precautions <a href="#Section_5.6">(5.6)</a>]</span></span><span class="Italics"><span class="Emphasis">.</span></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_2"></a><a name="section-2"></a><p></p>
<h1>2  DOSAGE AND ADMINISTRATION </h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1  Hypertension</h2>
<p class="First">Dosage must be individualized.  The usual starting dose of MICARDIS tablets is 40 mg once a day.  Blood pressure response is dose-related over the range of 20 to 80 mg <span class="Italics"><span class="Emphasis">[see Clinical Studies <a href="#Section_14.1">(14.1)</a>]</span></span>.</p>
<p>Most of the antihypertensive effect is apparent within 2 weeks and maximal reduction is generally attained after 4 weeks.  When additional blood pressure reduction beyond that achieved with 80 mg MICARDIS is required, a diuretic may be added.</p>
<p>No initial dosage adjustment is necessary for elderly patients or patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, including those on hemodialysis. Patients on dialysis may develop <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>; their blood pressure should be closely monitored.</p>
<p>MICARDIS tablets may be administered with other antihypertensive agents.</p>
<p>MICARDIS tablets may be administered with or without food.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2  Cardiovascular Risk Reduction</h2>
<p class="First">The recommended dose of MICARDIS tablets is 80 mg once a day and can be administered with or without food. It is not known whether doses lower than 80 mg of telmisartan are effective in reducing the risk of cardiovascular morbidity and mortality.</p>
<p>When initiating MICARDIS therapy for cardiovascular risk reduction, monitoring of blood pressure is recommended, and if appropriate, adjustment of medications that lower blood pressure may be necessary.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="Section_3"></a><a name="section-3"></a><p></p>
<h1>3  DOSAGE FORMS AND STRENGTHS</h1>
<ul class="Disc">
<li>20 mg, white or off-white, round, uncoated tablets imprinted with BI logo on one side and 50 H on the other side</li>
<li>40 mg, white or off-white, oblong, uncoated tablets imprinted with BI logo on one side and 51 H on the other side</li>
<li>80 mg, white or off-white, oblong, uncoated tablets imprinted with BI logo on one side and 52 H on the other side</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4"></a><a name="section-4"></a><p></p>
<h1>4  CONTRAINDICATIONS</h1>
<p class="First" style="border-left:1px solid;"><span class="XmChange"></span>MICARDIS is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> or <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>) to telmisartan or any other component of this product <span class="Italics"><span class="Emphasis">[see Adverse Reactions <a href="#Section_6.2">(6.2)</a>]</span></span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5"></a><a name="section-5"></a><p></p>
<h1>5  WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1  Fetal Toxicity</h2>
<p class="First"><span class="Bold"><span class="Emphasis">Pregnancy Category D</span></span></p>
<p>Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Resulting <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. When pregnancy is detected, discontinue MICARDIS as soon as possible  <span class="Italics"><span class="Emphasis">[see Use in Specific Populations <a href="#Section_8.1">(8.1)</a>]</span></span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2  Hypotension</h2>
<p class="First">In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> may occur after initiation of therapy with MICARDIS.  Either correct this condition prior to administration of MICARDIS, or start treatment under close medical supervision with a reduced dose.</p>
<p>If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> does occur, the patient should be placed in the supine position and, if necessary, given an intravenous infusion of normal saline.  A transient hypotensive response is not a contraindication to further treatment, which usually can be continued without difficulty once the blood pressure has stabilized.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3  Hyperkalemia</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> may occur in patients on ARBs, particularly in patients with advanced <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, on renal replacement therapy, or on potassium supplements, potassium-sparing diuretics, potassium-containing salt substitutes or other drugs that increase potassium levels. Consider periodic determinations of serum electrolytes to detect possible <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalances</span>, particularly in patients at risk.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4  Impaired Hepatic Function</h2>
<p class="First">As the majority of telmisartan is eliminated by biliary excretion, patients with biliary obstructive disorders or <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> can be expected to have reduced clearance.  Initiate telmisartan at low doses and titrate slowly in these patients <span class="Italics"><span class="Emphasis">[see Use in Specific Populations <a href="#Section_8.6">(8.6)</a> and Clinical Pharmacology <a href="#Section_12.3">(12.3)</a>]</span></span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5  Impaired Renal Function</h2>
<p class="First">As a consequence of inhibiting the renin-angiotensin-aldosterone system, anticipate changes in renal function in susceptible individuals.  In patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (e.g., patients with severe <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> or renal dysfunction), treatment with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor antagonists has been associated with <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> and/or progressive <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span> and (rarely) with <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and/or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Similar results have been reported with MICARDIS <span class="Italics"><span class="Emphasis">[see Clinical Pharmacology <a href="#Section_12.3">(12.3)</a>]</span></span>.</p>
<p>In studies of ACE inhibitors in patients with unilateral or <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">bilateral renal artery stenosis</span>, increases in serum creatinine or blood urea nitrogen were observed.  There has been no long term use of MICARDIS in patients with unilateral or <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">bilateral renal artery stenosis</span>, but anticipate an effect similar to that seen with ACE inhibitors.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6  Dual Blockade of the Renin-Angiotensin-Aldosterone System</h2>
<p class="First">As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function (including <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>) have been reported.   Dual blockade of the renin-angiotensin-aldosterone system (e.g., by adding an ACE-inhibitor to an angiotensin II receptor antagonist) should include close monitoring of renal function.</p>
<p>The ONTARGET trial enrolled 25,620 patients ≥55 years old with atherosclerotic disease or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> with end-organ damage, randomizing them to telmisartan only, ramipril only, or the combination, and followed them for a median of 56 months. Patients receiving the combination of MICARDIS and ramipril did not obtain any additional benefit compared to monotherapy, but experienced an increased incidence of renal dysfunction (e.g., acute
<span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>) compared with groups receiving telmisartan alone or ramipril alone.  Concomitant use of MICARDIS and ramipril is not recommended.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_6"></a><a name="section-6"></a><p></p>
<h1>6  ADVERSE REACTIONS</h1>
<p class="First">The following adverse reaction is described elsewhere in labeling:</p>
<p>        Renal dysfunction upon use with ramipril <span class="Italics"><span class="Emphasis">[see Warnings and Precautions <a href="#Section_5.6">(5.6)</a>]</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1  Clinical Trials Experience</h2>
<p class="First">Because clinical studies are conducted under widely varying conditions, adverse reactions rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.</p>
<p><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></span><br>
								MICARDIS has been evaluated for safety in more than 3700 patients, including 1900 treated for over 6 months and more than 1300 for over one year.  Adverse experiences have generally been mild and transient in nature and have infrequently required discontinuation of therapy.</p>
<p>In placebo-controlled trials involving 1041 patients treated with various doses of MICARDIS (20 to 160 mg) monotherapy for up to 12 weeks, the overall incidence of adverse events was similar to that in patients treated with placebo.</p>
<p>Adverse events occurring at an incidence of ≥1% in patients treated with MICARDIS and at a greater rate than in patients treated with placebo, irrespective of their causal association, are presented in Table 1.</p>
<p><span class="Bold"><span class="Emphasis">Table 1 Adverse Events Occurring at an Incidence of ≥1% in Patients Treated with MICARDIS and at a Greater Rate Than Patients Treated with Placebo</span></span></p>
<a name="ide202a40-179c-4a39-84a1-6ddbcae25a49"></a><table border="1" cellpadding="1" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="First">
<th align="center"> </th>
<th align="center">Telmisartan<br>n=1455<br>%</th>
<th align="center">Placebo<br>n=380<br>%</th>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td align="center">7</td>
<td align="center">6</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td align="center">3</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td align="center">3</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center">3</td>
<td align="center">2</td>
</tr>
<tr class="Last">
<td align="left"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></td>
<td align="center">1</td>
<td align="center">0</td>
</tr>
</tbody></table>
<p>In addition to the adverse events in the table, the following events occurred at a rate of ≥1% but were at least as frequent in the placebo group:  <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>-like symptoms, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>. Discontinuation of therapy because of adverse events was required in 2.8% of 1455 patients treated
with MICARDIS tablets and 6.1% of 380 placebo patients in placebo-controlled clinical trials.</p>
<p>The incidence of adverse events was not dose-related and did not correlate with gender, age, or race of patients.</p>
<p>The incidence of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> occurring with telmisartan in 6 placebo-controlled trials was identical to that noted for placebo-treated patients (1.6%).</p>
<p>In addition to those listed above, adverse events that occurred in more than 0.3% of 3500 patients treated with MICARDIS monotherapy in controlled or open trials are listed below.  It cannot be determined whether these events were causally related to MICARDIS tablets:</p>
<p><span class="Italics"><span class="Emphasis">Autonomic Nervous System</span></span>:  <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>; <span class="Italics"><span class="Emphasis">Body as a Whole</span></span>: <span class="Italics"><span class="Emphasis"></span></span><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">leg pain</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>; <span class="Italics"><span class="Emphasis">Cardiovascular</span></span>:  <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="4087149" conceptname="Dependent edema">dependent edema</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">leg edema</span>, <span class="product-label-link" type="condition" conceptid="320536" conceptname="Electrocardiogram abnormal">abnormal ECG</span>; <span class="Italics"><span class="Emphasis">CNS</span></span>:  <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, involuntary muscle contractions, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>; <span class="Italics"><span class="Emphasis">Gastrointestinal</span></span>:  <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="194382" conceptname="External hemorrhoids">hemorrhoids</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="201773" conceptname="Enteritis of small intestine">enteritis</span>, <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux</span>, <span class="product-label-link" type="condition" conceptid="4099176" conceptname="Toothache">toothache</span>, non-specific <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorders</span>; <span class="Italics"><span class="Emphasis">Metabolic</span></span>:  <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus; <span class="Italics"><span class="Emphasis">Musculoskeletal</span></span>:  <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>; <span class="Italics"><span class="Emphasis">Psychiatric</span></span>:  <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>; <span class="Italics"><span class="Emphasis">Resistance Mechanism</span></span>:  <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>,
<span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span>, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>, <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>; <span class="Italics"><span class="Emphasis">Respiratory</span></span>:  <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>; <span class="Italics"><span class="Emphasis">Skin</span></span>:  <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>; <span class="Italics"><span class="Emphasis">Urinary</span></span>:  micturition frequency, <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>; <span class="Italics"><span class="Emphasis">Vascular</span></span>: <span class="product-label-link" type="condition" conceptid="434056" conceptname="Late effects of cerebrovascular disease">cerebrovascular disorder</span>; and <span class="Italics"><span class="Emphasis">Special Senses</span></span>:  <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">earache</span>.</p>
<p>During initial clinical studies, a single case of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> was reported (among a total of 3781 patients treated).</p>
<p><span class="Italics"><span class="Emphasis">Clinical Laboratory Findings</span></span><br>
								In placebo-controlled clinical trials, clinically relevant changes in standard laboratory test parameters were rarely associated with administration of MICARDIS tablets.</p>
<p><span class="Underline">Hemoglobin</span>:  A greater than 2 g/dL decrease in hemoglobin was observed in 0.8% telmisartan patients compared with 0.3% placebo patients.  No patients discontinued therapy because of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>.</p>
<p><span class="Underline">Creatinine</span>:  A 0.5 mg/dL rise or greater in creatinine was observed in 0.4% telmisartan patients compared with 0.3% placebo patients.  One telmisartan-treated patient discontinued therapy because of increases in creatinine and blood urea nitrogen.</p>
<p><span class="Underline">Liver Enzymes</span>:  Occasional elevations of liver chemistries occurred in patients treated with telmisartan; all marked elevations occurred at a higher frequency with placebo.  No telmisartan-treated patients discontinued therapy because of abnormal hepatic function.</p>
<p><span class="Italics"><span class="Emphasis">Cardiovascular Risk Reduction</span></span><br>
								Because common adverse reactions were well characterized in studies of telmisartan in <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, only adverse events leading to discontinuation and serious adverse events were recorded in subsequent studies of telmisartan for cardiovascular risk reduction. In TRANSCEND (N=5926, 4 years and 8 months of follow-up), discontinuations for adverse events were 8.4% on telmisartan and 7.6% on placebo. The only serious adverse events at least 1% more common on telmisartan than placebo were <span class="product-label-link" type="condition" conceptid="442774" conceptname="Intermittent claudication">intermittent claudication</span> (7% vs 6%) and <span class="product-label-link" type="condition" conceptid="4262920" conceptname="Skin ulcer">skin ulcer</span> (3% vs 2%).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2  Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of MICARDIS. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure. Decisions to include these reactions in labeling are typically based on one or more of the following factors:  (1) seriousness of the reaction, (2) frequency of reporting, or (3) strength of causal connection to MICARDIS.</p>
<p>The most frequent spontaneously reported events include:  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, lower limb <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating increased</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">blood pressure increased</span>, <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">hypertension aggravated</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (including <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>), <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span> (including <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>), <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4148593" conceptname="Blood urate raised">uric acid increased</span>, abnormal hepatic function/<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">liver disorder</span>, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> including <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, increased CPK, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>, <span class="product-label-link" type="condition" conceptid="4068332" conceptname="Tenalgia">tendon pain</span> (including <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendonitis</span>, <span class="product-label-link" type="condition" conceptid="4195698" conceptname="Tenosynovitis">tenosynovitis</span>), <span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">drug eruption</span> (<span class="product-label-link" type="condition" conceptid="141370" conceptname="Toxic erythema">toxic skin eruption</span> mostly reported as <span class="product-label-link" type="condition" conceptid="141370" conceptname="Toxic erythema">toxicoderma</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>), <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (in diabetic patients), and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> (with fatal outcome).</p>
<p>Rare cases of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> have been reported in patients
receiving angiotensin II receptor blockers, including MICARDIS.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_7"></a><a name="section-7"></a><p></p>
<h1>7  DRUG INTERACTIONS</h1>
<p class="First"><span class="Italics"><span class="Emphasis">Digoxin</span></span>: When MICARDIS was co-administered with digoxin, median increases in digoxin peak plasma concentration (49%) and in trough concentration (20%) were observed. Therefore, monitor digoxin levels when initiating, adjusting, and discontinuing telmisartan for the purpose of keeping the digoxin level within the therapeutic range.</p>
<p><span class="Italics"><span class="Emphasis">Lithium</span></span>: Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists including MICARDIS. Therefore, monitor serum lithium levels during concomitant use.</p>
<p><span class="Italics"><span class="Emphasis">Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors):</span></span> In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including telmisartan, may result in deterioration of renal function, including possible <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>. These effects are usually reversible. Monitor renal function periodically in patients receiving telmisartan and NSAID therapy.</p>
<p>The antihypertensive effect of angiotensin II receptor antagonists, including telmisartan may be attenuated by NSAIDs including selective COX-2 inhibitors.</p>
<p><span class="Italics"><span class="Emphasis">Ramipril and Ramiprilat</span></span>: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy
subjects increases steady-state C<span class="Sub">max</span> and AUC of ramipril 2.3- and 2.1-fold, respectively, and C<span class="Sub">max</span> and AUC of ramiprilat 2.4- and 1.5-fold, respectively. In contrast, C<span class="Sub">max</span> and AUC of telmisartan decrease by 31% and 16%, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan. Concomitant use of MICARDIS and ramipril is not recommended.</p>
<p><span class="Italics"><span class="Emphasis">Other Drugs</span></span>: Co-administration of telmisartan did not result in a clinically significant interaction with acetaminophen, amlodipine, glyburide, simvastatin, hydrochlorothiazide, warfarin, or ibuprofen. Telmisartan is not metabolized by the cytochrome P450 system and had no effects <span class="Italics"><span class="Emphasis">in vitro</span></span> on cytochrome P450 enzymes, except for some inhibition of CYP2C19. Telmisartan is not expected to interact with drugs that inhibit cytochrome P450 enzymes; it is also not expected to interact with drugs metabolized by cytochrome P450 enzymes, except for possible inhibition of the metabolism of drugs metabolized by CYP2C19.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="Section_8"></a><a name="section-8"></a><p></p>
<h1>8  USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1  Pregnancy</h2>
<p class="First"><span class="Italics"><span class="Emphasis">Pregnancy Category D.  [See Warnings and Precautions <a href="#Section_">(5.1)</a>]</span></span>.</p>
<p>Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Resulting <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. When pregnancy is detected, discontinue MICARDIS as soon as possible. These adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. Appropriate management of maternal <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> during pregnancy is important to optimize outcomes for both mother and fetus.</p>
<p>In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. Perform serial ultrasound examinations to assess the intra-amniotic environment. If <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> is observed, discontinue MICARDIS, unless it is considered lifesaving for the mother. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of in utero exposure to MICARDIS for <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, and <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> <span class="Italics"><span class="Emphasis">[see Use in Specific Populations <a href="#Section_">(8.4)</a>]</span></span>.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="Section_8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3  Nursing Mothers</h2>
<p class="First">It is not known whether telmisartan is excreted in human milk, but telmisartan was shown to be present in the milk of lactating rats. Because of the potential for adverse effects on the nursing infant, decide whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Section_8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4  Pediatric Use</h2>
<p class="First"><span class="Underline"><span class="Emphasis">Neonates with a history of in utero exposure to MICARDIS:</span></span><br>
								If <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs, direct attention toward support of blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or substituting for disordered renal function.</p>
<p>Safety and effectiveness in pediatric patients have not been established <span class="Italics"><span class="Emphasis">[see Clinical Pharmacology <a href="#Section_12.3">(12.3)</a>] </span></span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Section_8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5  Geriatric Use</h2>
<p class="First">Of the total number of patients receiving MICARDIS in <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> clinical studies, 551 (19%) were 65 to 74 years of age and 130 (4%) were 75 years or older. No overall differences in effectiveness and safety were observed in these patients compared to younger patients and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
<p>Of the total number of patients receiving MICARDIS in the cardiovascular risk reduction study (ONTARGET), the percentage of patients ≥65 to &lt;75 years of age was 42%; 15% of patients were ≥75 years old. No overall differences in effectiveness and safety were observed in these patients compared to younger patients and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6  Hepatic Insufficiency</h2>
<p class="First">Monitor carefully and uptitrate slowly in patients with biliary obstructive disorders or <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> <span class="Italics"><span class="Emphasis">[see Warnings
and Precautions <a href="#Section_5.4">(5.4)</a>]</span></span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Section_10"></a><a name="section-9"></a><p></p>
<h1>10  OVERDOSAGE</h1>
<p class="First">Limited data are available with regard to overdosage in humans. The most likely manifestation of overdosage with MICARDIS tablets would be <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>; <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> could occur from parasympathetic (vagal) stimulation. If symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> should occur, supportive treatment should be instituted. Telmisartan is not removed by hemodialysis.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Section_11"></a><a name="section-10"></a><p></p>
<h1>11  DESCRIPTION</h1>
<p class="First">MICARDIS is a non-peptide angiotensin II receptor (type AT<span class="Sub">1</span>) antagonist.</p>
<p>Telmisartan is chemically described as 4'-[(1,4'-dimethyl-2'-propyl [2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid. Its empirical formula is C<span class="Sub">33</span>H<span class="Sub">30</span>N<span class="Sub">4</span>O<span class="Sub">2</span>, its molecular weight is 514.63, and its structural formula is:</p>
<p><img alt="Micardis structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3bb7bc69-7752-4c16-9c60-e61eb5355a4d&amp;name=image001.jpg"></p>
<p>Telmisartan is a white to slightly yellowish solid. It is practically insoluble in water and in the pH range of 3 to 9, sparingly soluble in strong acid (except insoluble in hydrochloric acid), and soluble in strong base.</p>
<p>MICARDIS is available as tablets for oral administration, containing 20 mg, 40 mg or 80 mg of telmisartan. The tablets contain the following inactive ingredients: sodium hydroxide, meglumine, povidone, sorbitol, and magnesium stearate. MICARDIS tablets are hygroscopic and require protection from moisture.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Section_12"></a><a name="section-11"></a><p></p>
<h1>12  CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="Section_12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1  Mechanism of Action</h2>
<p class="First">Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects
that include <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span>, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium.  Telmisartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT<span class="Sub">1</span> receptor in many tissues, such as vascular smooth muscle and the adrenal gland.  Its action is therefore independent of the pathways for angiotensin II synthesis.</p>
<p>There is also an AT<span class="Sub">2</span> receptor found in many tissues, but AT<span class="Sub">2</span> is not known to be associated with cardiovascular homeostasis. Telmisartan has much greater affinity (&gt;3,000 fold) for the AT<span class="Sub">1</span> receptor than for the AT<span class="Sub">2</span> receptor.</p>
<p>Blockade of the renin-angiotensin system with ACE inhibitors, which inhibit the biosynthesis of angiotensin II from angiotensin I, is widely used in the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. ACE inhibitors also inhibit the degradation of bradykinin, a reaction also catalyzed by ACE. Because telmisartan does not inhibit ACE (kininase II), it does not affect the response to bradykinin. Whether this difference has clinical relevance is not yet known. Telmisartan does not bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.</p>
<p>Blockade of the angiotensin II receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and angiotensin II circulating levels do not overcome the effect of telmisartan on blood pressure.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="Section_12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2  Pharmacodynamics</h2>
<p class="First">In normal volunteers, a dose of telmisartan 80 mg inhibited the pressor response to an intravenous infusion of angiotensin II by about 90% at peak plasma concentrations with approximately 40% inhibition persisting for 24 hours.</p>
<p>Plasma concentration of angiotensin II and plasma renin activity (PRA) increased in a dose-dependent manner after single administration of telmisartan to healthy subjects and repeated administration to hypertensive patients. The once-daily administration of up to 80 mg telmisartan to healthy subjects did not influence plasma aldosterone concentrations. In multiple dose studies with hypertensive patients, there were no clinically significant
changes in electrolytes (serum potassium or sodium), or in metabolic function (including serum levels of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, triglycerides, HDL, LDL, glucose, or uric acid).</p>
<p>In 30 hypertensive patients with normal renal function treated for 8 weeks with telmisartan 80 mg or telmisartan 80 mg in combination with hydrochlorothiazide 12.5 mg, there were no clinically significant changes from baseline in renal blood flow, glomerular filtration rate, filtration fraction, renovascular resistance, or creatinine clearance.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="Section_12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3  Pharmacokinetics</h2>
<p class="First">Following oral administration, peak concentrations (C<span class="Sub">max</span>) of telmisartan are reached in 0.5 to 1 hour after dosing. Food slightly reduces the bioavailability of telmisartan, with a reduction in the area under the plasma concentration-time curve (AUC) of about 6% with the 40 mg tablet and about 20% after a 160 mg dose. The absolute bioavailability of telmisartan is dose dependent. At 40 and 160 mg the bioavailability was 42% and 58%, respectively. The pharmacokinetics of orally administered telmisartan are nonlinear over the dose range 20 to 160 mg, with greater than proportional increases of plasma concentrations (C<span class="Sub">max </span>and AUC) with increasing doses. Telmisartan shows bi-exponential decay kinetics with a terminal elimination half life of approximately 24 hours. Trough plasma concentrations of telmisartan with once daily dosing are about 10% to 25% of peak plasma concentrations. Telmisartan has an accumulation index in plasma of 1.5 to 2.0 upon repeated once daily dosing.</p>
<p><span class="Italics"><span class="Emphasis">Distribution</span></span><br>
								Telmisartan is highly bound to plasma proteins (&gt;99.5%), mainly albumin and α<span class="Sub">1</span> - acid glycoprotein. Plasma protein binding is constant over the concentration range achieved with recommended doses. The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.</p>
<p><span class="Italics"><span class="Emphasis">Metabolism and Elimination</span></span><br>
								Following either intravenous or oral administration of <span class="Sup">14</span>C-labeled telmisartan, most of the administered dose (&gt;97%) was eliminated unchanged in feces via biliary excretion; only minute amounts were found in the urine (0.91% and 0.49% of total radioactivity, respectively).</p>
<p>Telmisartan is metabolized by conjugation to form a pharmacologically inactive acyl glucuronide; the glucuronide of the parent compound is the only metabolite that has been identified in human plasma and
urine. After a single dose, the glucuronide represents approximately 11% of the measured radioactivity in plasma. The cytochrome P450 isoenzymes are not involved in the metabolism of telmisartan.</p>
<p>Total plasma clearance of telmisartan is &gt;800 mL/min. Terminal half-life and total clearance appear to be independent of dose.</p>
<p><span class="Italics"><span class="Emphasis">Specific Populations</span></span><br><span class="Underline"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></span></span><br>
								No dosage adjustment is necessary in patients with decreased renal function. Telmisartan is not removed from blood by hemofiltration <span class="Italics"><span class="Emphasis">[see Warnings and Precautions <a href="#Section_5.5">(5.5)</a> and Dosage and Administration <a href="#Section_2.1">(2.1)</a>]</span></span>.<br><br><span class="Underline"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></span></span><br>
								In patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>, plasma concentrations of telmisartan are increased, and absolute bioavailability approaches 100% <span class="Italics"><span class="Emphasis">[see Warnings and Precautions <a href="#Section_5.4">(5.4)</a> and Use in Specific Populations <a href="#Section_8.6">(8.6)</a>]</span></span>.<br><br><span class="Underline"><span class="Emphasis">Gender</span></span><br>
								Plasma concentrations of telmisartan are generally 2 to 3 times higher in females than in males. In clinical trials, however, no significant increases in blood pressure response or in the incidence of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> were found in women. No dosage adjustment is necessary.<br><br><span class="Underline"><span class="Emphasis">Geriatric Patients</span></span><br>
								The pharmacokinetics of telmisartan do not differ between the elderly and those younger than 65 years <span class="Italics"><span class="Emphasis">[see Dosage and Administration <a href="#Section_2.1">(2.1)</a>]</span></span>.<br><br><span class="Underline"><span class="Emphasis">Pediatric Patients</span></span><br>
								Telmisartan pharmacokinetics have not been investigated in patients &lt;18 years of age.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="Section_13"></a><a name="section-12"></a><p></p>
<h1>13  NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">There was no evidence of carcinogenicity when telmisartan was administered in the diet to mice and rats for up to 2 years. The highest doses administered to mice (1000 mg/kg/day) and rats (100 mg/kg/day) are, on a mg/m<span class="Sup">2</span> basis, about 59 and 13 times, respectively, the maximum recommended human dose (MRHD) of telmisartan. These same doses have been shown to provide average systemic exposures to telmisartan &gt;100 times and &gt;25 times, respectively, the systemic exposure in humans receiving the MRHD (80 mg/day).</p>
<p>Genotoxicity assays did not reveal any telmisartan-related effects at either the gene or chromosome level. These assays included bacterial mutagenicity tests with <span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span></span> and <span class="Italics"><span class="Emphasis">E. coli</span></span> (Ames), a gene mutation test with Chinese hamster V79 cells, a cytogenetic test with human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, and a mouse micronucleus test.</p>
<p>No drug-related effects on the reproductive performance of male and female rats were noted at 100 mg/kg/day (the highest dose administered), about 13 times, on a mg/m<span class="Sup">2</span> basis, the MRHD of
telmisartan. This dose in the rat resulted in an average systemic exposure (telmisartan AUC as determined on day 6 of pregnancy) at least 50 times the average systemic exposure in humans at the MRHD (80 mg/day).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_13.3"></a><a name="section-12.2"></a><p></p>
<h2>13.3  Developmental Toxicity</h2>
<p class="First">There is no clinical experience with the use of MICARDIS tablets in pregnant women. No teratogenic effects were observed when telmisartan was administered to pregnant rats at oral doses of up to 50
mg/kg/day and to pregnant rabbits at oral doses up to 45 mg/kg/day. In rabbits, embryolethality associated with maternal toxicity (reduced body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> and food consumption) was observed at 45 mg/kg/day [about 12 times the maximum recommended human dose (MRHD) of 80 mg on a mg/m<span class="Sup">2 </span>basis]. In rats, maternally toxic (reduction in body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> and food consumption) telmisartan doses of 15 mg/kg/day (about 1.9 times the MRHD on a mg/m<span class="Sup">2 </span>basis), administered during late gestation and lactation, were observed to produce adverse effects in neonates, including reduced viability, low birth weight, delayed maturation, and decreased <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. Telmisartan has been shown to
be present in rat fetuses during late gestation and in rat milk. The no observed effect doses for developmental toxicity in rats and rabbits, 5 and 15 mg/kg/day, respectively, are about 0.64 and 3.7 times, on a mg/m<span class="Sup">2 </span>basis,
the maximum recommended human dose of telmisartan (80 mg/day).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="Section_14"></a><a name="section-13"></a><p></p>
<h1>14  CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1  Hypertension</h2>
<p class="First">The antihypertensive effects of MICARDIS have been demonstrated in six principal placebo-controlled clinical trials, studying a range of 20 to 160 mg; one of these examined the antihypertensive effects of telmisartan and hydrochlorothiazide in combination. The studies involved a total of 1773 patients with mild to moderate <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (diastolic blood pressure of 95 to 114 mmHg), 1031 of whom were treated with telmisartan. Following once daily
administration of telmisartan, the magnitude of blood pressure reduction from baseline after placebo subtraction was approximately (SBP/DBP) 6-8/6 mmHg for 20 mg, 9-13/6-8 mmHg for 40 mg, and 12-13/7-8 mmHg for 80 mg. Larger doses (up to 160 mg) did not appear to cause a further decrease in blood pressure.</p>
<p>Upon initiation of antihypertensive treatment with telmisartan, blood pressure was reduced after the first dose, with a maximal reduction by about 4 weeks. With cessation of treatment with MICARDIS tablets,
blood pressure gradually returned to baseline values over a period of several days to one week. During long term studies (without placebo control) the effect of telmisartan appeared to be maintained for up to at least one year. The antihypertensive effect of telmisartan is not influenced by patient age, gender, weight, or body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index. Blood pressure response in black patients (usually a low-renin population) is noticeably less than that in Caucasian patients. This has been true for most, but not all, angiotensin II antagonists and ACE inhibitors.</p>
<p>In a controlled study, the addition of telmisartan to hydrochlorothiazide produced an additional dose-related reduction in blood pressure that was similar in magnitude to the reduction achieved with telmisartan monotherapy. Hydrochlorothiazide also had an added blood pressure effect when added to telmisartan.</p>
<p>The onset of antihypertensive activity occurs within 3 hours after administration of a single oral dose. At doses of 20, 40, and 80 mg, the antihypertensive effect of once daily administration of telmisartan is
maintained for the full 24-hour dose interval. With automated ambulatory blood pressure monitoring and conventional blood pressure measurements, the 24-hour trough-to-peak ratio for 40 to 80 mg doses of telmisartan was 70 to 100% for both
systolic and diastolic blood pressure. The incidence of symptomatic orthostasis after the first dose in all controlled trials was low (0.04%).</p>
<p>There were no changes in the heart rate of patients treated with telmisartan in controlled trials.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.2"></a><a name="section-13.2"></a><p></p>
<h2>14.2  Cardiovascular Risk Reduction</h2>
<p class="First">Support for use to reduce the
risk of cardiovascular events was obtained in a pair of studies. Both enrolled
subjects age ≥55 years, at high cardiovascular risk as evidenced by <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> (75%), <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>
mellitus (27%) accompanied with end-organ damage (e.g., <span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">retinopathy</span>, left
<span class="product-label-link" type="condition" conceptid="4145489" conceptname="Ventricular hypertrophy">ventricular hypertrophy</span>, and, in ONTARGET only, macro- or <span class="product-label-link" type="condition" conceptid="4195061" conceptname="Microalbuminuria">microalbuminuria</span>),
<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> (16%), <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disease</span> (13%), or transient ischemic attack
(4%). Patients without a history of intolerance to ACE inhibitors entered
ONTARGET, and those with such a history, usually <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> (90%), entered TRANSCEND,
but patients with &gt;1+ <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> on dipstick were excluded from TRANSCEND. For both ONTARGET and TRANSCEND trials, the primary
4-component composite endpoint was <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from cardiovascular causes, myocardial
<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, and hospitalization for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. The secondary
3-component composite endpoint was <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from cardiovascular causes, myocardial
<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.</p>
<p>ONTARGET was a randomized, active-controlled, multinational,
double-blind study in 25,620 patients who were randomized to telmisartan 80 mg,
ramipril 10 mg, or their combination.  The population studied was 73%
male, 74% Caucasian, 14% Asian, and 57% were 65 years of age or older. 
Baseline therapy included acetylsalicylic acid (76%), lipid lowering agents
(64%), beta-blockers (57%), calcium channel blockers (34%), nitrates (29%), and
diuretics (28%).  The mean duration of follow up was about 4 years and 6
months.  During the study, 22.0% (n=1878) of telmisartan patients
discontinued the active treatment, compared to 24.4% (n=2095) of ramipril
patients and 25.3% (n=2152) of telmisartan/ramipril patients.</p>
<p>TRANSCEND randomized patients
to telmisartan 80 mg (n=2954) or placebo (n=2972). The mean duration of follow
up was 4 years and 8 months. The
population studied was 57% male, 62% Caucasian, 21% Asian, and 60% were 65
years of age or older.  Baseline therapy included acetylsalicylic acid
(75%), lipid lowering agents (58%), beta-blockers (58%), calcium channel
blockers (41%), nitrates (34%) and diuretics (33%). During the study, 17.7%
(n=523) of telmisartan patients discontinued the active treatment, compared to
19.4% (n=576) of placebo patients.</p>
<p>The results for the TRANSCEND
trial are summarized in Table 2, and the results for ONTARGET are summarized in
Table 3, below:</p>
<a name="i1b78b47f-2765-493f-848d-08c7694cf972"></a><table border="0" cellpadding="1" width="100%">
<caption><span>Table 2 Incidence of the Primary and Secondary Outcomes from TRANSCEND</span></caption>
<tfoot><tr class="First Last Toprule"><td align="left" colspan="4">
<span class="Sup">*</span>The primary endpoint was defined as the time to first event. In case of multiple simultaneous events, all individual events were considered; the sum of patients with
 individual outcomes may exceed the number of patients with composite (primary or secondary) outcomes.
<br><span class="Sup">**</span>For individual components of the primary composite endpoints, all events, regardless whether or not they were the first event, were considered. Therefore, they are more than the first events considered for the primary or secondary composite endpoint.</td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<th class="Lrule Toprule" rowspan="2"> </th>
<th class="Lrule Rrule Toprule" align="left" colspan="3">Telmisartan vs. Placebo<br>
 (n=2954) (n=2972)</th>
</tr>
<tr class="Botrule">
<td class="Lrule"><span class="Bold"><span class="Emphasis">No. of Events<br>
 Telmisartan / Placebo</span></span></td>
<td class="Lrule"><span class="Bold"><span class="Emphasis">Hazard Ratio<br>
 95% CI</span></span></td>
<td class="Lrule Rrule"><span class="Bold"><span class="Emphasis">p-value</span></span></td>
</tr>
<tr class="Botrule">
<td class="Lrule">
<span class="Sup">*</span>Composite of CV <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, or hospitalization for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span></td>
<td class="Lrule">465 (15.7%) / 504 (17.0%)</td>
<td class="Lrule">0.92 (0.81 – 1.05)</td>
<td class="Lrule Rrule">0.2129</td>
</tr>
<tr class="Botrule">
<td class="Lrule">
<span class="Sup">*</span>Composite of CV <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></td>
<td class="Lrule">384 (13.0%) / 440 (14.8%)</td>
<td class="Lrule">0.87 (0.76 – 1.00)</td>
<td class="Lrule Rrule">0.0483</td>
</tr>
<tr class="Botrule">
<td class="Lrule">Individual components of the primary composite endpoint</td>
<td class="Lrule"><span class="Bold"><span class="Emphasis">No. of Events<br>
 Telmisartan / Placebo</span></span></td>
<td class="Lrule"><span class="Bold"><span class="Emphasis">Hazard Ratio<br>
 95% CI</span></span></td>
<td class="Lrule Rrule"><span class="Bold"><span class="Emphasis">p-value</span></span></td>
</tr>
<tr class="Botrule">
<td class="Lrule">    <span class="Sup">**</span>All non-fatal MI</td>
<td class="Lrule">114 (3.9%) / 145 (4.9%)</td>
<td class="Lrule">0.79 (0.62 – 1.01)</td>
<td class="Lrule Rrule">0.0574</td>
</tr>
<tr class="Last">
<td class="Lrule">    <span class="Sup">**</span>All non-fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span></td>
<td class="Lrule">112 (3.8%) / 136 (4.6%)</td>
<td class="Lrule">0.83 (0.64 – 1.06)</td>
<td class="Lrule Rrule">0.1365</td>
</tr>
</tbody>
</table>
<a name="if28aab37-df3d-4ac0-86be-33bf4a3fbd00"></a><table border="1" cellpadding="1" width="100%">
<caption><span>Table 3 Incidence of the Primary and Secondary Outcomes from ONTARGET</span></caption>
<tbody class="Headless">
<tr class="First">
<th class="Lrule Toprule" rowspan="2"> </th>
<th align="left" colspan="2">Telmisartan vs. Ramipril<br>
								(n=8542) (n=8576)</th>
</tr>
<tr>
<td><span class="Bold"><span class="Emphasis">No. of Events<br>
								Telmisartan / Ramipril</span></span></td>
<td><span class="Bold"><span class="Emphasis">Hazard Ratio<br>
								97.5% CI</span></span></td>
</tr>
<tr>
<td>Composite of CV <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, or hospitalization for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span></td>
<td>1423 (16.7%) / 1412 (16.5%)</td>
<td>1.01 (0.93 – 1.10)</td>
</tr>
<tr class="Last">
<td>Composite of CV <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></td>
<td>1190 (13.9%) / 1210 (14.1%)</td>
<td>0.99 (0.90 – 1.08)</td>
</tr>
</tbody>
</table>
<p>Although
the event rates in ONTARGET were similar on telmisartan and ramipril, the
results did not unequivocally rule out that MICARDIS may not preserve a
meaningful fraction of the effect of ramipril in reducing cardiovascular events. However, the
results of both ONTARGET and TRANSCEND do adequately support MICARDIS being
more effective than placebo would be in this setting, particularly for the end point
of time to cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.</p>
<p>In ONTARGET, there was no
evidence that combining ramipril and MICARDIS reduced the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from
cardiovascular causes, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, or hospitalization for heart
failure greater than ramipril alone; instead, patients who received the
combination of ramipril and telmisartan in ONTARGET experienced an increased
incidence of clinically important renal dysfunction (e.g., <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>)
compared to patients receiving MICARDIS or ramipril alone.</p>
<p>Multiple sub-group analyses
did not demonstrate any differences in the 4-component composite primary
endpoint based on age, gender, or ethnicity for either ONTARGET or TRANSCEND
trial.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_16"></a><a name="section-14"></a><p></p>
<h1>16  HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">MICARDIS is available as white or off-white, uncoated tablets containing telmisartan 20 mg, 40 mg, or 80 mg. Tablets are marked with the BOEHRINGER INGELHEIM logo on one side, and on the other side, with either 50H, 51H, or 52H for the 20 mg, 40 mg, and 80 mg strengths, respectively. Tablets are provided as follows:</p>
<p>MICARDIS tablets 20 mg are round and individually <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>-sealed in cartons of 30 tablets as 3 x 10 cards (NDC 54868-6193-0).</p>
<p>MICARDIS tablets 40 mg are oblong shaped and individually <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>-sealed in cartons of 30 tablets as 3 x 10 cards (NDC 54868-4539-1).</p>
<p>MICARDIS tablets 80 mg are oblong shaped and individually <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>-sealed in cartons of 30 tablets as 3 x 10 cards (NDC 54868-4605-1) and individually <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>-sealed in cartons of 9 x 10 cards (NDC 54868-4605-2).</p>
<p><span class="Italics"><span class="Emphasis">Storage</span></span><br><span class="Bold"><span class="Emphasis">Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F)</span></span> [see USP Controlled Room Temperature]. Tablets should not be removed from <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> until immediately before administration.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Section_17"></a><a name="section-15"></a><p></p>
<h1>17  PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics"><span class="Emphasis">See FDA-approved Patient Labeling</span></span></p>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_17.1"></a><a name="section-15.1"></a><p></p>
<h2>17.1  Pregnancy</h2>
<p class="First">Female patients of childbearing age should be told about the consequences of exposure to MICARDIS during pregnancy.  Discuss treatment options with women planning to become pregnant. Patients should be asked to report pregnancies to their physicians as soon as possible <span class="Italics"><span class="Emphasis">[see Warnings and Precautions <a href="#Section_5.1">(5.1)</a>]</span></span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.3"></a><a name="section-15.2"></a><p></p>
<h2></h2>
<p class="First">Distributed by:<br>
								Boehringer Ingelheim Pharmaceuticals, Inc.<br>
								Ridgefield, CT 06877 USA</p>
<p>Licensed from: Boehringer Ingelheim International GmbH, Ingelheim, Germany</p>
<p>Copyright 2012 Boehringer Ingelheim International GmbH<br>
								ALL RIGHTS RESERVED</p>
<p>OT1200SA252012<br>
								090340194/12</p>
<p>IT12004O<br>
								10005385/9</p>
<br><p><br></p>
<p><span class="Bold">Additional barcode labeling by:</span><br>Physicians Total Care, Inc.<br>Tulsa, Oklahoma        74146<br></p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="Section_18"></a><a name="section-16"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold"><span class="Emphasis">Patient Information</span></span></p>
<p><span class="Bold"><span class="Emphasis">MICARDIS<span class="Sup">®</span> (my-CAR-dis)</span></span><br><span class="Bold"><span class="Emphasis">(telmisartan)<br>
						Tablets</span></span></p>
<p>Read this Patient Information before you start taking MICARDIS tablets and each time you get a refill. There may be new information. This information does not take the place of talking to your doctor about your medical condition or your treatment.</p>
<p><span class="Bold"><span class="Emphasis">What is the most important information I should know about MICARDIS tablets?</span></span></p>
<p>MICARDIS can cause harm or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to an unborn baby. Talk to your doctor about other ways to lower your blood pressure if you plan to become pregnant. If you get pregnant while taking MICARDIS, tell your doctor right away.</p>
<p><span class="Bold"><span class="Emphasis">What is MICARDIS? </span></span></p>
<p>MICARDIS is a prescription medicine used:</p>
<ul class="Disc">
<li>to treat high blood pressure (<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>)</li>
<li>in certain high risk people aged 55 years and older to help lower their risk of having certain cardiovascular problems such as <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></li>
</ul>
<p>It is not known if MICARDIS is safe and effective in children.</p>
<p><span class="Bold"><span class="Emphasis">Who should not take MICARDIS?</span></span></p>
<p>You should not take MICARDIS tablets if you are allergic (hypersensitive) to the active ingredient (telmisartan) or any of the other ingredients listed at the end of this leaflet.</p>
<p><span class="Bold"><span class="Emphasis">What should I tell my doctor before taking MICARDIS tablets?</span></span></p>
<p>Before you take MICARDIS tablets, tell your doctor if you:</p>
<ul class="Disc">
<li>have liver problems</li>
<li>have kidney problems</li>
<li>have heart problems</li>
<li>have any other medical conditions</li>
<li>are pregnant or are planning to become pregnant. See <span class="Bold"><span class="Emphasis">"What is the most important information I should
know about MICARDIS tablets?"</span></span>
</li>
<li>are breast-feeding or plan to breast-feed. It is not known if MICARDIS passes into your breast milk. You and your doctor should decide if you will take MICARDIS tablets or breast-feed. You should not do both. Talk with your doctor about the best way to feed your baby if you take MICARDIS tablets.</li>
</ul>
<p><span class="Bold"><span class="Emphasis">Tell your doctor about all the medicines you take, </span></span>including prescription and non-prescription medicines, vitamins, and herbal supplements.</p>
<p>MICARDIS may affect the way other medicines work, and other medicines may affect how MICARDIS works. Especially tell your doctor if you take:</p>
<ul class="Disc">
<li>digoxin (Lanoxin<span class="Sup">®</span>, Lanoxicaps<span class="Sup">®</span>)</li>
<li>lithium (Eskalith<span class="Sup">®</span>, Lithobid<span class="Sup">®</span>)</li>
<li>medicines used to treat <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, called non-steroidal anti-inflammatory drugs (NSAIDs), including COX-2 inhibitors</li>
<li>ramipril (Altace<span class="Sup">®</span>) or other medicines used to treat your high blood pressure or heart problem</li>
<li>water pills (diuretic)</li>
</ul>
<p>Know the medicines you take. Keep a list of them and show it to your doctor or pharmacist when you get a new medicine.</p>
<p><span class="Bold"><span class="Emphasis">How should I take MICARDIS tablets?</span></span></p>
<ul class="Disc">
<li>Take MICARDIS tablets exactly as your doctor tells you to take it.</li>
<li>Your doctor will tell you how much MICARDIS to take and when to take it.</li>
<li>Do not change your dose unless your doctor tells you to.</li>
<li>Take MICARDIS one time each day at the same time.</li>
<li>Take MICARDIS tablets with or without food.</li>
<li> If you miss a dose, take it as soon as you remember. If it is close to your next dose, do not take the missed dose. Take the
 next dose at your regular time.</li>
<li> If you take too much MICARDIS, call your doctor, or go to the nearest hospital emergency room right away.</li>
<li>Read the <span class="Bold"><span class="Emphasis">"How to Open the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span>"</span></span> at the end of  this leaflet before you use MICARDIS. Talk with your doctor if you do not understand the instructions.</li>
</ul>
<p><span class="Bold"><span class="Emphasis">What are the possible side effects of MICARDIS tablets?</span></span></p>
<p><span class="Bold"><span class="Emphasis">MICARDIS tablets may cause serious side effects, including:</span></span></p>
<ul class="Disc">
<li>
<span class="Bold"><span class="Emphasis">Injury or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to your unborn baby.</span></span> See <span class="Bold"><span class="Emphasis">"What is the most important information I should know about MICARDIS tablets?"</span></span>
</li>
<li>
<span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Low blood pressure</span> (<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>)</span></span> is most likely to happen if you also:
								<ul class="Disc">
<li>take water pills (diuretics)</li>
<li>are on a low-salt diet</li>
<li>get dialysis treatments</li>
<li>have heart problems</li>
<li>get sick with <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
</ul>
</li>
</ul>
<dl class="None">
<dt> </dt>
<dd><span class="Bold"><span class="Emphasis">If you feel <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span> or dizzy, lie down and call your doctor right away.</span></span></dd>
</dl>
<ul class="Disc"><li>
<span class="Bold"><span class="Emphasis">Kidney problems</span></span>, which may get worse if you already have kidney  disease. You may have changes in your kidney test results, and you may need a lower dose of MICARDIS tablets. Call your doctor if you get:
							<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in your feet, ankles, or hands</li>
<li>unexplained <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span></li>
</ul>
</li></ul>
<dl class="None">
<dt> </dt>
<dd><span class="Bold"><span class="Emphasis">Call your doctor right away if you get any of the symptoms listed above.</span></span></dd>
</dl>
<ul class="Disc"><li>
<span class="Bold"><span class="Emphasis">High potassium in the blood (<span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>). </span></span> Your doctor may check your potassium levels as needed.</li></ul>
<p>Rare, serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> may happen. Tell your doctor right away if you get any of these symptoms:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the  face, tongue, throat</li>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span></li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span></li>
</ul>
<p><span class="Bold"><span class="Emphasis">The most common side effects of MICARDIS tablets include:</span></span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4172302" conceptname="Sinus headache">sinus pain</span> and congestion (<span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
</ul>
<p>These are not all the possible side effects with MICARDIS tablets. Tell your doctor if you have any side effect that bothers you or that does not go away. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold"><span class="Emphasis">How should I store MICARDIS tablets?</span></span></p>
<ul class="Disc">
<li>Store MICARDIS tablets between 59°F to 86°F (15°C to 30°C).</li>
<li>Do not remove MICARDIS tablets from <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> until right before you take them.</li>
</ul>
<p><span class="Bold"><span class="Emphasis">Keep MICARDIS tablets and all medicines out of the reach of children.</span></span></p>
<p><span class="Bold"><span class="Emphasis">General information about MICARDIS tablets</span></span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use MICARDIS tablets for a condition for which it was not prescribed. Do not give MICARDIS
tablets to other people, even if they have the same condition you have. It may harm them.</p>
<p>This Patient Information leaflet summarizes the most important information about MICARDIS tablets. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for
information about MICARDIS tablets that is written for health professionals.</p>
<p>For more information, call Boehringer Ingelheim Pharmaceuticals, Inc. at 1-800-542-6257, or (TTY) 1-800-459-9906.</p>
<p><span class="Bold"><span class="Emphasis">What are the ingredients in MICARDIS tablets?</span></span></p>
<p><span class="Bold"><span class="Emphasis">Active Ingredient:</span></span> telmisartan</p>
<p><span class="Bold"><span class="Emphasis">Inactive Ingredients:</span></span> sodium hydroxide, meglumine, povidone, sorbitol, and magnesium stearate </p>
<p><span class="Bold"><span class="Emphasis">What is High Blood Pressure (<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>)? </span></span></p>
<p>Blood pressure is the force in your blood vessels when your heart beats and when your heart rests. You have high blood pressure when the force is too much.  MICARDIS tablets can help your blood vessels relax so your blood pressure is lower. High blood pressure makes the heart work harder to pump blood throughout the body and causes damage to the blood vessels. If high blood pressure is not treated, it can lead to <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span>, and vision problems.</p>
<p><span class="Bold"><span class="Emphasis">What is Cardiovascular Risk?</span></span></p>
<p>Patients older than 55 years of age who have been diagnosed with blood vessel disease in the heart, legs, or brain (coronary, peripheral, or cerebral vascular disease) or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> with end organ damage (for example: kidney, heart, and brain) are at higher risk of cardiovascular events (for example: <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from cardiovascular causes, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, and/or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>).</p>
<p><span class="Bold"><span class="Emphasis">How to open the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>:</span></span></p>
<p>1. Tear (You may  also use scissors to tear the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> apart)<br><img alt="Tear the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> apart" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3bb7bc69-7752-4c16-9c60-e61eb5355a4d&amp;name=image002.jpg"></p>
<p>2. Peel (Peel off the paper layer from the aluminum foil)<br><img alt="Peel off the paper layer from the aluminum foil" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3bb7bc69-7752-4c16-9c60-e61eb5355a4d&amp;name=image003.jpg"></p>
<p>3. Push (Push the tablet through the foil)<br><img alt="Push (Push the tablet through the foil)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3bb7bc69-7752-4c16-9c60-e61eb5355a4d&amp;name=image004.jpg"></p>
<p>Distributed by:<br>
						Boehringer Ingelheim Pharmaceuticals, Inc.<br>
						Ridgefield, CT 06877 USA</p>
<p>Licensed from: Boehringer Ingelheim International GmbH, Ingelheim, Germany</p>
<p>Copyright 2012 Boehringer Ingelheim International GmbH<br>
						ALL RIGHTS RESERVED</p>
<p>Revised: January 2012</p>
<p>OT1200SA252012<br>
						090340194/12</p>
<p>IT12004O<br>
						10005385/9</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s19"></a><a name="section-17"></a><p></p>
<h1></h1>
<p class="First">Micardis</p>
<p>20 mg</p>
<p>30 Tablets</p>
<p>NDC 54868-6193-0</p>
<div class="Figure"><img alt="Micardis 20 mg 30 Tablets" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3bb7bc69-7752-4c16-9c60-e61eb5355a4d&amp;name=6193.jpg"></div>
<br><p>Micardis</p>
<p>40 mg</p>
<p>30 Tablets</p>
<p>NDC 54868-4539-1</p>
<div class="Figure"><img alt="Micardis 40 mg 30 Tablets" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3bb7bc69-7752-4c16-9c60-e61eb5355a4d&amp;name=4539.jpg"></div>
<br><p>Micardis</p>
<p>80 mg</p>
<p>30 Tablets</p>
<p>NDC 54868-4605-1<br></p>
<div class="Figure"><img alt="Micardis 80 mg 30 Tablets" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3bb7bc69-7752-4c16-9c60-e61eb5355a4d&amp;name=4605.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MICARDIS 		
					</strong><br><span class="contentTableReg">telmisartan tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-6193(NDC:0597-0039)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TELMISARTAN</strong> (TELMISARTAN) </td>
<td class="formItem">TELMISARTAN</td>
<td class="formItem">20 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MEGLUMINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SORBITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">50H;</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-6193-0</td>
<td class="formItem">3  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020850</td>
<td class="formItem">11/02/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MICARDIS 		
					</strong><br><span class="contentTableReg">telmisartan tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-4539(NDC:0597-0040)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TELMISARTAN</strong> (TELMISARTAN) </td>
<td class="formItem">TELMISARTAN</td>
<td class="formItem">40 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MEGLUMINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SORBITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">51H;</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-4539-1</td>
<td class="formItem">3  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020850</td>
<td class="formItem">01/19/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MICARDIS 		
					</strong><br><span class="contentTableReg">telmisartan tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-4605(NDC:0597-0041)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TELMISARTAN</strong> (TELMISARTAN) </td>
<td class="formItem">TELMISARTAN</td>
<td class="formItem">80 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MEGLUMINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SORBITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">52H;</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-4605-1</td>
<td class="formItem">3  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-4605-2</td>
<td class="formItem">9  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020850</td>
<td class="formItem">03/25/2002</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>d6d6402a-3913-4adf-b6e6-f4676533a3a5</div>
<div>Set id: 3bb7bc69-7752-4c16-9c60-e61eb5355a4d</div>
<div>Version: 5</div>
<div>Effective Time: 20120214</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
